David Elsley
Gründer bei CARDIOL THERAPEUTICS INC.
Vermögen: 2 Mio $ am 30.04.2024
Aktive Positionen von David Elsley
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CARDIOL THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 19.01.2017 | - |
Vorstandsvorsitzender | 19.01.2017 | - | |
Gründer | 19.01.2017 | - | |
Präsident | 19.01.2017 | - |
Karriereverlauf von David Elsley
Ehemalige bekannte Positionen von David Elsley
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Direktor/Vorstandsmitglied | 01.01.1990 | 23.10.2009 |
Gründer | 01.01.1990 | 23.10.2009 |
Ausbildung von David Elsley
Richard Ivey School of Business | Masters Business Admin |
University of Western Ontario | Masters Business Admin |
Statistik
International
Kanada | 5 |
Operativ
Director/Board Member | 2 |
Founder | 2 |
Masters Business Admin | 2 |
Sektoral
Health Technology | 3 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
CARDIOL THERAPEUTICS INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
- Börse
- Insiders
- David Elsley
- Erfahrung